Core Insights - The company reported a strong organic sales growth of 9% in the first half of the year, with an upward revision of the full-year guidance to a range of 6-8% [1][3] - Profitability remains solid despite currency headwinds, with an adjusted EBITDA margin of 37.4%, up by 210 basis points compared to the previous quarter [3] - The company achieved cost synergies at a 100% run rate, indicating improved operational efficiency [3] Sales Performance - Organic sales growth in the Food & Health segment reached 10%, while the Planetary Health segment saw a growth of 9% [3] - Emerging markets experienced a robust organic sales growth of 12%, compared to 8% in developed markets [3] Financial Metrics - Adjusted net profit increased by 23%, reflecting strong financial performance [3] - The company maintained a net interest-bearing debt to EBITDA ratio of 2.1x, following the acquisition of dsm-firmenich's part of the Feed Enzyme Alliance [3] Shareholder Returns - A share buyback program worth EUR 100 million was completed on June 27, enhancing shareholder value [3] - An interim dividend of 2.25 DKK (EUR 0.30) was approved for the first half of 2025 [3] Future Outlook - The company has narrowed its 2025 organic sales growth outlook to 6-8%, with a range of 7-9% excluding exits from certain countries [3] - Long-term financial targets for 2030 have been announced, indicating a strategic focus on growth and investment in unique biosolutions [1][3]

Core Insights - Novonesis has announced its 'GROW' strategy, aiming for long-term growth with a focus on core business acceleration and significant reinvestments until 2030 [1][2] - The company targets an organic sales CAGR of 6-9%, an adjusted EBITDA margin of approximately 39%, and an adjusted ROIC excluding goodwill of around 16% by 2030 [1][6] Business Strategy - The strategy emphasizes strong performance in biosolutions, leveraging deep customer understanding, innovation, and scalability to meet increasing demand driven by population growth, energy needs, and climate risks [1][2] - Novonesis plans to explore new growth areas, including Biopharma Processing Aids, Future Fuels and Chemicals, and Specialized Nutrition Proteins, targeting applications with significant untapped potential [2] Financial Projections - Organic sales growth is expected to be primarily driven by volume and annual price contributions of 1-2%, with emerging markets anticipated to grow faster than developed markets [6] - The adjusted EBITDA margin is projected to be around 39% by 2030, with a significant investment in innovation and market capabilities to support both short- and long-term growth [6] - The adjusted ROIC excluding goodwill is expected to rise from a pro forma 8.3% in 2024 to approximately 16% by 2030 [6] Capital Expenditure and Financial Management - Capital expenditures (Capex) will be elevated at the beginning of the strategy period to support sustained high growth, gradually decreasing to high-single-digit percentages of sales towards the end of the period [6] - The company targets a net debt/EBITDA ratio of around 1.5x and maintains a clear capital allocation model with an expected dividend payout ratio of 40-60% of adjusted net profit [6]